Literature DB >> 8699991

Progressive glomerular toxicity of ifosfamide in children.

V K Prasad1, I J Lewis, S R Aparicio, D Heney, J P Hale, C C Bailey, S E Kinsey.   

Abstract

Glomerular toxicity following ifosfamide (IFO) is not as well recognized as renal tubular damage. Following a case of ifosfamide-induced renal failure with histological evidence of glomerular changes, we undertook a retrospective study of all IFO-treated children to assess the extent and severity of its glomerular toxicity and to identify possible predisposing factors. Thirty-seven children with a follow-up of 6 months or more from the end of chemotherapy were studied. They were a median of 10.8 years old (range 3.25-18.5), had received a median of 54 g/m2 (range 9-135) of IFO, and had a median follow-up of 29 months (range 6-68). The criteria to identify glomerular dysfunction were raised plasma creatinine (Pc) values on two occasions or a low glomerular filtration rate (GFR) measured by Tc-99-DTPA clearance. Detailed assessment was carried out to identify other nephrotoxic influences in these children. Subjects in whom glomerular dysfunction could be causally linked to IFO were compared with the rest of the group for a variety of predisposing factors. Of eight children with glomerular dysfunction, two had other nephrotoxic influences and were excluded from further analysis. In six (17.1%) children, glomerular dysfunction appeared to be causally linked to IFO. Their median GFR was 61.9 ml/min/1.73 m2(range 33-85) and Pc was 123 mumol/l (range 85-216). Five of the six had normal glomerular function at the end of therapy and the raised Pc values were first noted 19, 21, 26, 29, and 36 months later. Children with glomerular toxicity had a significantly longer median follow-up (41.5 vs. 19 months; P = 0.04) than the rest of the group, suggesting late onset of this problem. They were older at the time of the study and had received nearly twice the dose of IFO, though the differences in age and dose did not reach statistical significance. The earliest signs of renal toxicity were seen in the index case, who had had prior nephrectomy. All affected children had coexistent and preceding tubular toxicity. The inadequacies of tests commonly used to assess glomerular function and the possibility of underestimation of dysfunction are discussed. Glomerular dysfunction following IFO is poorly recognized and evidence from this study of its later onset and progressive nature is a cause for concern. The index case is described with histological findings.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8699991     DOI: 10.1002/(SICI)1096-911X(199609)27:3<149::AID-MPO3>3.0.CO;2-E

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  10 in total

Review 1.  Drug-induced acute kidney injury in children.

Authors:  Lauren N Faught; Michael J E Greff; Michael J Rieder; Gideon Koren
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

Review 2.  Renal late effects in patients treated for cancer in childhood: a report from the Children's Oncology Group.

Authors:  Deborah P Jones; Sheri L Spunt; Daniel Green; James E Springate
Journal:  Pediatr Blood Cancer       Date:  2008-12       Impact factor: 3.167

Review 3.  Chemotherapy-associated renal dysfunction.

Authors:  Vaibhav Sahni; Devasmita Choudhury; Ziauddin Ahmed
Journal:  Nat Rev Nephrol       Date:  2009-06-30       Impact factor: 28.314

4.  Improvement in karyomegalic interstitial nephritis three years after ifosfamide and cisplatin therapy by corticosteroid.

Authors:  Tomokazu Matsuura; Shu Wakino; Ayumi Yoshifuji; Toshifumi Nakamura; Hirobumi Tokuyama; Akinori Hashiguchi; Konosuke Konishi; Takeshi Iwasa; Masaaki Shoji; Ako Hosono; Ken Ohashi; Hirokazu Chuman; Hiroshi Itoh
Journal:  CEN Case Rep       Date:  2014-06-04

5.  Late-onset kidney failure in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Bryan V Dieffenbach; Qi Liu; Andrew J Murphy; Deborah R Stein; Natalie Wu; Arin L Madenci; Wendy M Leisenring; Nina S Kadan-Lottick; Emily R Christison-Lagay; Robert E Goldsby; Rebecca M Howell; Susan A Smith; Kevin C Oeffinger; Yutaka Yasui; Gregory T Armstrong; Christopher B Weldon; Eric J Chow; Brent R Weil
Journal:  Eur J Cancer       Date:  2021-08-11       Impact factor: 10.002

6.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11

7.  Risk factors for nephrotoxicity after ifosfamide treatment in children: a UKCCSG Late Effects Group study. United Kingdom Children's Cancer Study Group.

Authors:  R Skinner; S J Cotterill; M C Stevens
Journal:  Br J Cancer       Date:  2000-05       Impact factor: 7.640

8.  Ifosfamide/etoposide alternating with high-dose methotrexate: evaluation of a chemotherapy regimen for poor-risk osteosarcoma.

Authors:  M P Michelagnoli; I J Lewis; H R Gattamaneni; C C Bailey; L S Lashford
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

9.  Osteomalacia as a late metabolic complication of Ifosfamide chemotherapy in young adults: illustrative cases and review of the literature.

Authors:  D N Church; A B Hassan; S J Harper; C J Wakeley; C G A Price
Journal:  Sarcoma       Date:  2007

Review 10.  Late renal toxicity of treatment for childhood malignancy: risk factors, long-term outcomes, and surveillance.

Authors:  Roderick Skinner
Journal:  Pediatr Nephrol       Date:  2017-04-22       Impact factor: 3.714

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.